Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)
Sponsor: Active Biotech AB
A PHASE1/PHASE2 clinical study on Post-Essential Thrombocytosis Myelofibrosis and Post-polycythemia Vera Myelofibrosis, this trial is actively recruiting participants. The trial is conducted by Active Biotech AB and has accumulated 9 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
Status: Active Not Recruiting → Recruiting · Phase: PHASE2 → PHASE1/PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Mar 2025 — Jul 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 4 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
May 2024 — Jun 2024 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2024 — May 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Active Biotech AB
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .